Psychiatr. praxi 2017; 18(3): 120-124 | DOI: 10.36290/psy.2017.022

Trends in pharmacotherapy of unipolar depression

MUDr. Tomáš Novák, Ph.D.
Národní ústav duševního zdraví, Klecany
3. lékařská fakulta Univerzity Karlovy, Praha

Unipolar depression is a severe mental disease with high prevalence but response to treatment strategies remains unsatisfactory ina substantial part of patients. The development of new antidepressants and testing agents with antidepressive action represent themajor trends to improve this challenging situation. Current guidelines attempts to integrate new findings into recommendationsfor various situations in clinical practice. A paper provides a brief overview of current trends in pharmacotherapy of depression.

Keywords: unipolar depression, antidepressants, acute treatment, maintenance treatment

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novák T. Trends in pharmacotherapy of unipolar depression. Psychiatr. praxi. 2017;18(3):120-124. doi: 10.36290/psy.2017.022.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rubio JM, Markowitz JC, Alegria A, et al. Epidemiology of chronic and nonchronic major depressive disorder: results from the national epidemiologic survey on alcohol and related conditions. Depress Anxiety. 2011; 28: 622-631. Go to original source... Go to PubMed...
    2. Hardeveld F, Spijker J, de Graaf R, et al. Recurrence of major depressive disorder across different treatment settings: results from the NESDA study. J Affect Disord. 2013; 147: 225-231. Go to original source... Go to PubMed...
    3. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013; 10: e1001547. Go to original source... Go to PubMed...
    4. Regier DA, Narrow WE, Clarke DE, et al. DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses. Am J Psychiatry. 2013; 170(1): 59-70. Go to original source... Go to PubMed...
    5. Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013; 14(5): 334-385. Go to original source... Go to PubMed...
    6. Bauer M, Severus E, Köhler S, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015; 16(2): 76-95. Go to original source... Go to PubMed...
    7. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015; 29(5): 459-525. Go to original source... Go to PubMed...
    8. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016; 61(9): 540-60. Go to original source... Go to PubMed...
    9. Taylor D, Paton C, Kapur S, ed. The Maudsley Prescribing Guidelines in Psychiatry, 12th edition. Wiley Blackwell, Oxford, UK, 2015, pp741.
    10. Raboch J. Psychiatrie: doporučené postupy psychiatrické péče IV. Praha: Česká lékařská společnost J.E. Purkyně, 2014. 208 s.
    11. Höschl C. Agomelatin - antidepresivum, jež obnovuje cirkadiánní rytmy. Remedia 2012; 22: 186-193
    12. Mohr P, Melicher T, Knytl P. Vortioxetin: přehled nového antidepresiva. Psychiatr. praxi 2016; 17(1): 31-32. Go to original source...
    13. Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Human Psychopharmacology. 2014; 29(5): 470-482. Go to original source... Go to PubMed...
    14. Hayasaka Y, Purgato M, Magni LR, et al. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. J Affect Disord. 2015; 180: 179-84. Go to original source... Go to PubMed...
    15. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology. 2002; 161(2): 143-151. Go to original source... Go to PubMed...
    16. Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ. 2002; 325(7371): 991. Go to original source... Go to PubMed...
    17. Yildiz A, Sachs GS. Administration of antidepressants. Single versus split dosing: a meta-analysis. J Affect Disord 2001; 66: 199-206. Go to PubMed...
    18. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665): 746-758. Go to original source... Go to PubMed...
    19. Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev. 2003; (2): CD004186. Go to original source...
    20. Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol. 2007; 22(6): 323-329. Go to original source... Go to PubMed...
    21. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011; 168(7): 689-701. Go to original source... Go to PubMed...
    22. Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015; 76(4): e487-498. Go to original source... Go to PubMed...
    23. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003; 361(9358): 653-661. Go to original source... Go to PubMed...
    24. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.